David Mosedale

David Mosedale is a seasoned professional in the life sciences sector with extensive experience in various leadership roles. Currently serving as VP of ProQuant at RXCELERATE LIMITED since April 2023, Mosedale was previously the Chief Technology Officer at Methuselah Health UK Ltd., where work involved studying proteome instability in age-related diseases. Prior to that, Mosedale held the position of Chief Scientific Officer at Total Scientific Ltd., overseeing contract research services. Additional roles include VP of Research and Development at Pronostics Ltd., where responsibilities encompassed multiplex diagnostic tests development, and Principal Investigator at Papworth Hospital NHS Foundation Trust, leading significant clinical studies. Mosedale began professional training as a post-doctoral researcher at the University of Cambridge after earning an MA in Biochemistry from the same institution.